MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade.

By Peter Ebert, J. Cheung, Yagai Yang, Erin McNamara, Rebecca Hong, M. Moskalenko, S. Gould, H. Maecker, B. Irving, J. Kim and 2 more. Immunity, 2016

654 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/7b6be7418755866413bf5ac52cc15dd64343f24e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. N. Sharpless
2. Nathanael S. Gray
3. Julia Salzman
4. Ling-Ling Chen
5. J. Campisi

In Oncology

1. D. Barbie
2. Russell W. Jenkins
3. Nathanael S. Gray
4. L. Emens

Citations in the corpus

• CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation (2017, background): “The digested NFATc3 and His-GB1 were separated and further purified using size exclusion chromatography (GE Healthcare Life Sciences “Superdex 75 10/300 GL”).”
• Breast Cancer Immunotherapy: Facts and Hopes (2017, background): “Although MEK inhibitors have been shown to block naïve T cell priming in tumor-bearing mice, they can increase the number of effector CD8 T cells by preventing activation-induced cell death, leaving effector T cell activity intact (64).”